Crossmark

Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis

Crossref DOI link: https://doi.org/10.1186/s40425-019-0577-1

Published Online: 2019-04-02

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Abu-Sbeih, Hamzah

Ali, Faisal S.

Wang, Xuemei

Mallepally, Niharika

Chen, Ellie

Altan, Mehmet

Bresalier, Robert S.

Charabaty, Aline

Dadu, Ramona

Jazaeri, Amir

Lashner, Bret

Wang, Yinghong https://orcid.org/0000-0002-5148-6130
License Information

Text and Data Mining valid from 2019-04-02
More Information

Article History

Received: 31 January 2019

Accepted: 22 March 2019

First Online: 2 April 2019

Ethics approval and consent to participate

: The ethics approval of this study was granted by the IRB committee at the University of Texas MD Anderson Cancer Center (PA18–0472). The consent was waived for this study.

: This study was granted waiver for consent.

: The authors declare that they have no conflict of interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below